Levodopa fractionated dose composition and use
AssigneeAvion Pharmaceuticals, LLC
InventorsThomas N Chase, Kathleen E. Clarence-Smith
Life of this patent
Estimating the term…
Abstract
There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.
Claims29
A method for the treatment of Parkinson's disease or related levodopa (LD)-responsive disorders, comprising orally administering to a patient in need thereof, carbidopa/levodopa (CD/LD) at an effective dose to simulate continuous intravenous administration of LD, up to 9 times per day,
- wherein the effective dose comprises CD within a range of 6.25 mg to 18.75 mg and LD within a range of 25 mg to 75 mg, and
- wherein entacapone is not concurrently administered.
A method for the treatment of Parkinson's disease or levodopa (LD)-responsive disorders in a patient who is hypersensitive to LD, comprising orally administering to the patient, carbidopa/levodopa (CD/LD) at an effective dose to simulate continuous intravenous administration of LD, up to 9 times per day,
- wherein the effective dose comprises CD within a range of 6.25 mg to 18.75 mg and LD within a range of 25 mg to 75 mg, and
- wherein entacapone is not concurrently administered.
A method of treating, alleviating, or delaying the onset of, motor response complications related to Parkinson's disease or related levodopa (LD)-responsive disorder, comprising orally administering to a patient in need thereof, carbidopa/levodopa (CD/LD) at an effective dose to simulate continuous intravenous administration of LD, up to 9 times per day,
- wherein the effective dose comprises CD within a range of 6.25 mg to 18.75 mg and LD within a range of 25 mg to 75 mg, and
- wherein entacapone is not concurrently administered.
Dependencies are inferred from the claim text.